|Ran Nussbaum – Chairman
Ran is a managing partner and co-founder of The Pontifax Group. Pontifax operates six different funds with more than 75 portfolio companies worldwide. In addition, Pontifax has established more than 19 startups since it was incorporated in 2005.
Ran’s work revolves around constant and active involvement in companies, providing them with strategic and business development oversight. Currently Ran sits on the board of many of Pontifax’s portfolio companies, including Keros Therapeutics (as Chairman of the Board), Eloxx Pharmaceuticals Inc (NASDAQ: ELOX), UroGen Pharma (NASDAQ: URGN), Prevail Therapeutics (NASDAQ: PRVL) and Lutris Pharma. Previously, Ran served on the board of Kite Pharma (sold to Gilead) and cCEM Therapeutics (sold to Merck), as Chairman of the Board of OCON and NasVax, and as CEO of Spearhead and Biomedix.
|Jasbir Seehra, Ph.D.
Jasbir Seehra is the founding CEO of Keros Therapeutics. Jas worked with the academic founders and Pontifax in putting together the strategy and in-licensing of the founding technology. Jas brings more than 30 years of scientific, strategic and operational experience in Biotech industry.
Prior to Keros, Dr. Seehra was the CSO at Ember Therapeutics, founded by Third Rock Ventures. In 2003, Jas co-founded Acceleron Pharma, focused on biologics inhibiting the TGFb superfamily and served as CSO to the end of 2010. Jas hired the research team that discovered multiple products and manufacturing teams and oversaw the discovery and development of multiple products targeting muscle strength, bone loss and anemia. As founder and member of the executive team, Jas helped raise more than $200M capital from venture fund and corporate partnerships with Celgene and Shire.
Jas spent 20 years at Genetics Institute and then Wyeth Pharmaceutics starting in 1983 as a bench scientist, holding numerous positions with increasing responsibility. Dr. Seehra successfully built the small molecule drug discovery capability at Genetics Institute and after the merger with Wyeth, he led the small molecule lead discovery as VP of Biological Chemistry.
He received his undergraduate and graduate degrees in Biochemistry from the University of Southampton UK. Dr. Seehra completed his postdoctoral work with Professor H. Gobind Khorana at the Massachusetts Institute of Technology. Dr. Seehra has numerous publications and is an inventor on more than 70 patents.
| Julius Knowles
Jay Knowles is a Partner at Partners Innovation Fund, the venture arm of Partners HealthCare. Partners was founded by Massachusetts General Hospital (MGH) and Brigham and Women’s Hospital (BWH), the two principal teaching hospitals of the Harvard Medical School. At Partners, Jay focuses on creating and helping to grow drug discovery companies.
|Alon Lazarus, Ph.D.
Alon Lazarus is a Biotech Investment Manager for Arkin Holdings’ Pharma Division. He is a member of the Board of several of its pharmaceutical companies, including Oncorus, Lutris Pharma, Redpin Therapeutics and Explore Bio.
Prior to joining Arkin, Alon Lazarus worked for the Healthcare Business Development Department of Yissum – the Research & Development arm of the Hebrew University and as an analyst for the University’s Integra Holdings. Alon holds a Ph.D in Molecular Biology and an MBA – both from the Hebrew University of Jerusalem in Israel.
Ohad is a Partner at Pontifax, where he is in charge of scouting and project evaluation. In his role at Pontifax, Ohad is also involved in the formation and development strategy of the fund’s early-stage portfolio companies. He serves as a director in Metabomed, Dynacure, Camel-IDS, Eyevensys and Horama. Ohad obtained his M.S. in Biology from Tel-Aviv University.
Zafi Avnur Ms. Avnur was named Distinguished Scientist, the highest scientific appointment at Roche.
Ms. Avnur was named Distinguished Scientist, the highest scientific appointment at Roche.